SVSuphi Vehid

Suphi Vehid

*This is an algorithmically generated author record based on publicly available information.

Suphi Vehid has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Distribution of Aerobic and Anaerobic Bacteria in the Etiology of Granulomatous Mastitis and Their Resistance to Antimicrobial Agents

    by Zeynep Taner, Mehmet Velidedeoğlu, Bilgul Mete, Mehmet Demirci, Fatih Dal, Suphi Vehid, Yasemin Kucuk, Ertugrul Goksoy, Varol Celik, Harika Oyku Dinc, et al.

    GİRİŞ Mastitler, memenin inflamasyonu ile seyreden infeksiyöz ya da noninfeksiyöz hastalıklar olup genellikle kadınları etkiler (1). Mastitler; laktasyonel mastit, non-laktasyonel mastit ve meme apsesi olmak üzere üç grupta incelenmektedir. Non-laktasyonel mastit; santral veya subareolar infeksiyon, periferal infeksiyon ve granülomatöz infeksiyon olmak üzere üç gruba ayrılır (1). İnfeksiyöz olmayan mastit (non-laktasyonel mastit), memenin lobüllerinde genişleme ile […]


  • Open Access

    Effects of Short-message Notifications on Type 2 Diabetes Management in Middle-aged Turkish Patients: A Randomized Trial

    by Bernard Tahirbegolli, Iliriana Alloqi Tahirbegolli, Ramazan Çakmak, Cemile İdIz, Sabanur Çavdar, Elif Bağdemir, Suphi Vehid


  • Open Access

    Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

    by Zekayi Kutlubay, Ayşegül SEVİM KEÇİCİ, Övgü Aydin, Suphi Vehi̇d, Server Serdaroğlu

    Background and Objectives Alopecia areata is an inflammatory disease with a genetic and autoimmune basis. We aimed to study the efficacy, and safety of an immunomodulatory therapeutic agent, diphenylcyclopropenone, while manifesting the association with histopathological features, prognostic factors and side effects. Materials and Methods In this retrospective study, 98 patients (60 men, 38 women) with alopecia who were referred to the ?Hair Disease Polyclinic? at Department of Dermatology between 2011 and 2015 were included. Together with medical histories and dermatological examinations, all patients were taken a skin biopsy for histopathological examination prior to the therapy. Therapeutic success was evaluated on the basis of hair re-growth percentage. Results Regarding the overall treatment success, 33 (34%) patients had complete response, 16 (16%) patients had partial response (between 50-99%), 27 (28%) patients had minimal response (between 1-49%), and 22 (22%) patients were non-responders. Both genders were equally represented in the outcome. Conclusions There was a significant relation between the severity of alopecia and treatment outcome. (p=0.038) Patients with alopecia areata had significantly better response when compared to alopecia totalis and universalis. There was no statistically significant relation with other parameters such as disease duration, age, gender, atopy history, age of onset, and histopathological features.


  • Open Access

    Comparison of truview EVO2 and macintosh laryngoscopes in infants

    by C. Tutuncu, G. Kaya, G. Meyanci, Y. Tunali, T. Utku, S. Vehid


  • Open Access

    Effects of Low and High Doses of Atorvastatin on Arterial Compliance.

    by Yesari Karter, Asli Çurgunlu, Nurver Ertürk, Suphi Vehid, Ismail Mihmanli, Faruk Ayan

    At the beginning of atherosclerosis before evidence of morphological lesions or plaques, vascular distensibility or arterial compliance decreased gradually. This endothelial dysfunction is regarded as an early feature of atherosclerosis. In a randomized, double-blind study design, group I (12 patients; 7 males, 5 females) with serum LDL-C levels higher than 170 mg/dL and without any other risk factor for atherosclerosis received three months of 20 mg/day atorvastatin treatment while group II (8 males, 4 females) with the same characteristics received 80 mg/day. Baseline and posttreatment serum lipid fractions and arterial compliance were measured. Arterial compliance was measured noninvasively in the left common carotid artery with color Doppler ultrasound. Atorvastatin reduced total cholesterol (TC), LDL-C, and triglyceride levels by 32% (P < 0.001), 40.8% (P < 0.001), and 19% (P < 0.001), respectively, and increased HDL-C by 6.9% (P = 0.002) in the first group. In the second group these reductions were 38.5% (P < 0.001), 46.2% (P < 0.001), and 26.78% (P < 0.001), respectively, and the increase in HDL was 7.8% (P = 0.03). It was observed that the decrease in serum TC, LDL-C and triglyceride levels were significantly higher in the second group than the first group. With atorvastatin, the distensibility coefficient (DC) and compliance coefficient (CC) increased from 18.7 ± 3.4 to 21.3 ± 2.9 10-3.kPa-1 (P < 0.001) and from 0.69 ± 0.05 to 0.77 ± 0.03 mm2.kPa-1 (P < 0.001) in the first group while they changed from 18.3 ± 3.6 to 21.9 ± 3.0 10-3.kPa-1 (P < 0.001) and from 0.70 ± 0.04 to 0.81 ± 0.01 mm2.kPa-1 (P < 0.001) respectively, in the second group. DC and CC increased in both groups, but the differences between the groups were not significant. High doses of atorvastatin reduce blood lipid levels more than conventional doses, however, the change in compliance is not dose-dependent. As endothelial dysfunction is regarded as an early feature of atherosclerosis, there would be no need to administer aggressive doses in a patient without any risk factors other than hyperlipidemia.